Henry Schein Inc. has announced a major leadership transition, appointing Emmanuel Caprais as the new Chief Financial Officer (CFO), effective November 4, 2026. This change comes as Ronald South, the current CFO, will transition to the role of Senior Advisor after overseeing the company's third-quarter earnings process. The appointment of Caprais is expected to bring a fresh perspective to the company’s financial strategies and operations.
Henry Schein Inc. operates in the wholesale medical, dental, and hospital equipment and supplies sector, a critical industry that supports healthcare providers across the nation. The company, listed on the Nasdaq under the ticker HSIC, has been a significant player in this sector, providing essential products and services to healthcare professionals.
According to the recent SEC filing (accession number 0001193125-26-417409), Ronald South will remain in his position until November 3, 2026, after which he will assume the role of Senior Advisor. In the interim, the company has structured a transition plan for Caprais, who will initially serve as Senior Financial Advisor starting October 12, 2026, before officially taking over as CFO.
Emmanuel Caprais, 51, joins Henry Schein from ITT Inc., where he served as Senior Vice President and CFO from 2020 until May 2026. His extensive background includes various finance leadership roles at ITT, where he was responsible for financial planning, analysis, and investor relations. Caprais also held significant positions at Magneti Marelli and Valeo, enhancing his qualifications for the CFO role at Henry Schein.
In connection with his appointment, Caprais will receive an annual base salary of $750,000, with a target annual bonus opportunity of $750,000 under the company’s Incentive Plan. He will also be eligible for a one-time cash sign-on bonus of $25,000, along with participation in the company's long-term incentive program, which is expected to grant him equity awards valued at $2.5 million in 2027.
The filing indicates that Caprais’s employment is at will and not for a fixed term, allowing for flexibility in his role. Furthermore, he will be subject to a Restrictive Covenant Agreement that includes non-compete and non-solicitation clauses, ensuring his commitment to the company’s interests.
Henry Schein's transition in leadership could have broader implications for the wholesale medical equipment industry. As Caprais steps into his new role, competitors may be closely monitoring how his strategies and decisions will impact the market. The healthcare supply sector is competitive, and new leadership often signals shifts in company direction and operational focus.
The filing does not specify what the next steps will be following this leadership change, but the company’s focus on a structured transition suggests an emphasis on maintaining stability during this period. Stakeholders will be looking for updates on how Caprais’s leadership will shape Henry Schein’s future.